Bruno Besteiro, Manuel Marques da Cruz, Cláudia Alves, Fátima Costa, Mariana Nunes, Daniel Martinho Dias, Ana Barreira, Joana Calvão, Mónica Mesquita, Sónia Carvalho, Inês Pinho, Paulo Carrola, José Presa Ramos
BACKGROUND AND AIMS: Carvedilol has emerged as the preferred β-blocker for treating portal hypertension. However, there is still a debate in dosing regimen, with a potential lower bioavailability in once-daily regimens. The aim of this study is to assess the acute effects of carvedilol posology in patients with clinically significant portal hypertension (CSPH), as a surrogate marker of bioavailability. METHODS: In this experimental study, 34 patients with CSPH receiving carvedilol twice daily were asked to suppress the night dose of carvedilol, creating a standardized 24-hour dose interval...
March 11, 2024: European Journal of Gastroenterology & Hepatology